In Vivo Development of Ertapenem Resistance in a Patient with Pneumonia Caused by Klebsiella pneumoniae with an Extended-Spectrum -Lactamase
Open Access
- 1 June 2006
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (11) , e95-e98
- https://doi.org/10.1086/503264
Abstract
Four sequential extended-spectrum β-lactamase—producing isolates of Klebsiella pneumoniae were obtained from a patient after treatment with ertapenemKeywords
This publication has 8 references indexed in Scilit:
- BSAC standardized disc susceptibility testing method (version 4)Journal of Antimicrobial Chemotherapy, 2005
- In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)Journal of Antimicrobial Chemotherapy, 2005
- Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical CenterAntimicrobial Agents and Chemotherapy, 2004
- Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UKJournal of Antimicrobial Chemotherapy, 2004
- Role of β-Lactamases and Porins in Resistance to Ertapenem and Other β-Lactams in Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2004
- Properties and potential of ertapenemJournal of Antimicrobial Chemotherapy, 2003
- Activity of Ertapenem (MK-0826) versus Enterobacteriaceae with Potent β-LactamasesAntimicrobial Agents and Chemotherapy, 2001
- Porin expression in clinical isolates of Klebsiella pneumoniaeMicrobiology, 1999